Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

CFS 2011 /
Active angiogenesis drugs in development

20th May 2011

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.11.11
Views: 3432

Prof Bradley Monk – University of California Irvine, USA

Speaking on denosumab, the first active, targeted agent in epithelial ovarian cancer, Prof Bradley Monk meets with ecancertv at the Chemotherapy Foundation Symposium in New York City.

Prof Monk also discusses other active angiogenesis molecules that target pathways such as VEGF trap, which is a FC fusion molecule, AMG 386 and multiple anti angiogenesis molecules in phase III studies. 

Other new targets in development are folate receptors, which allow for the targeting of specific ovarian cancer cells and stimulate an immune response.  These receptors are currently in phase II studies.  Lastly, Prof Monk mentions EC 145, a vitamin that is administered in conjunction with chemotherapy, PARP inhibitors, and continuing research cytotoxics.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation